Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Voyageur Pharmaceuticals ( (TSE:VM) ) has shared an update.
Voyageur Pharmaceuticals has confirmed that barium sulfate sourced from its Frances Creek property meets and exceeds pharmaceutical-grade standards, with independent SGS testing showing an average purity of 98.8% BaSO4 and full compliance with USP monograph and particle size requirements. The material processed efficiently into ultra-fine, micronized particles under GMP conditions, which management views as a major de-risking milestone that validates the quality and cost advantages of its natural barite resource.
Supported by an Alberta Innovates AICE-Market Access Program grant, the company is now progressing to stage two of the program as it completes manufacturing of barium contrast agents for a Health Canada-compliant human clinical trial. The upcoming study will compare Voyageur’s contrast products against existing barium-based and iodinated oral agents in gastrointestinal CT and fluoroscopic applications, potentially paving the way for commercial use and strengthening its competitive position in the medical imaging supply chain.
The most recent analyst rating on (TSE:VM) stock is a Sell with a C$0.16 price target. To see the full list of analyst forecasts on Voyageur Pharmaceuticals stock, see the TSE:VM Stock Forecast page.
Spark’s Take on TSE:VM Stock
According to Spark, TipRanks’ AI Analyst, TSE:VM is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and rising cash burn that implies funding/dilution risk), only partly offset by low leverage and positive equity. Technical indicators are broadly neutral and provide limited support, while valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on TSE:VM stock, click here.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian developer of pharmaceutical-grade barium and iodine products used as medical imaging contrast media. The company sources natural barite from its Frances Creek property in British Columbia and aims to build an integrated, cost-effective North American supply chain for barium contrast agents, targeting gastrointestinal CT and fluoroscopic imaging markets.
Average Trading Volume: 95,701
Technical Sentiment Signal: Buy
Current Market Cap: C$26.79M
For a thorough assessment of VM stock, go to TipRanks’ Stock Analysis page.